Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 485 participants.
Also called NCT01353469
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 485 participants
- Sponsor
- Registry
-
NCT01353469
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01353469. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy
- Acronym
- Insuman-C25-CN
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Insulin human/Insuman Comb 25 (HR1799)
- Intervention (Drug)
- Insulin human/Novolin® 30R
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01353469- Content hash
47904ab85d5bc3334a338dbbeb5c44e1600da2beeb5ec7dee0d50a934a0faa4b